← 返回

肉瘤:CD73 与 PD-L1 的相关性及其与预后的关系

英文原题:Sarcoma - correlation between CD73 and PD-L1 and their relationship with prognosis.

查看英文原题

Sarcoma - correlation between CD73 and PD-L1 and their relationship with prognosis.

PubMed 2022/01/01(内容时间) Pol J Pathol Q4 · IF 0.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

本研究旨在评估肉瘤患者中CD73和PD-L1的表达,确定二者之间的关系及其与总生存期(OS)的关联。分析了101例患者的石蜡包埋组织块。女性占56.4%,患者平均年龄51.39岁。OS平均为20.73个月,Ki-67增殖指数平均为41.45。发现CD73肿瘤表达与TIL(肿瘤浸润淋巴细胞)中CD73表达呈正相关。CD73肿瘤及TIL表达也与PD-L1阳性比例和PD-L1染色强度呈正相关。OS与CD73肿瘤及TIL表达呈负相关;对于CD73表达比例为5%–25%、25%–50%、50%–75%、75%–90%和>90%的组,均观察到这种关系,但5%组无此相关性。OS与PD-L1阳性比例达到50%、以及PD-L1弱至中等或强染色强度呈负相关,但与PD-L1阴性无相关性。

最后,OS与Ki-67增殖指数呈负相关。我们发现,CD73和PD-L1阳性与肉瘤患者OS降低相关,且二者之间存在显著相关性。这一发现提示,对经选择的患者采用抗CD73和抗PD-L1疗法,有望改善生存并控制疾病。

展开英文摘要原文

This study aimed to evaluate CD73 and PD-L1 and determine their relationship with each other and with overall survival (OS) in sarcoma patients. The paraffin blocks of 101 patients were analysed. 56. 4% were female, and the mean age was 51. 39 years. The mean OS was 20. 73 months, and the Ki-67 proliferative index was 41. 45. A positive correlation was found between CD73 tumour and CD73 tumour-infiltrating lymphocyte (TIL) findings. CD73 tumour and TIL findings were also positively correlated with PD-L1 percentages and PD-L1 intensity.

An inverse correlation was detected between OS and CD73 tumour and TIL groups of 5-25%, 25-50%, 50-75%, 75-90%, and > 90%, but no such correlation was found for the 5% group. There was an inverse correlation between OS and the PD-L1 percentages of 50% and the PD-L1 intensity of weak-moderate and strong, but no correlation was found for the negative values. Lastly, an inverse correlation was found between OS and the Ki-67 proliferative index.

We found CD73 and PD-L1 positivity to be associated with decreased OS in sarcoma patients and determined a significant correlation between these parameters. This result is promising in terms of achieving better survival and disease control with anti-CD73 and anti-PD-L1 therapy in selected patients.

论文信息

作者
Yetişir AE、Paydaş S、Gönlüşen G、Erdoğan KE、Büyükşimşek M、Oğul A、Tohumcuoğlu M、Mirili C
第一作者单位
Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey.Turkey
通讯作者单位
Department of Physical Medicine and Rehabilitation, Çukurova University Faculty of Medicine, Adana, Turkey.Turkey
期刊
Polish journal of pathology : official journal of the Polish Society of Pathologists2022
原文标识
PubMed 36946270 · DOI 10.5114/pjp.2022.125537